Skip to main content
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1995 Feb;48(2):110–114. doi: 10.1136/jcp.48.2.110

Changes in transferrin saturation after treatment with the oral iron chelator deferiprone in patients with iron overload.

F N al-Refaie 1, C E De Silva 1, B Wonke 1, A V Hoffbrand 1
PMCID: PMC502372  PMID: 7745107

Abstract

AIMS--To evaluate the changes in transferrin saturation in patients with iron overload following the oral administration of the iron chelator deferiprone; to assess the correlation between the degree of transferrin desaturation, the deferiprone dose, and urinary iron excretion. METHODS--Serum samples were obtained from 16 patients with iron overload at different time intervals following the oral administration of deferiprone (50 mg/kg). These samples were analysed using 6M urea/polyacrylamide gel electrophoresis (UPAGE). This method is able to resolve serum transferrin into four different forms (free iron, two forms of monoferric, and diferric). The deferiprone concentration in these samples was estimated using high pressure liquid chromatography (HPLC). Zero time samples (t0) from 10 patients were incubated with 150 microM deferiprone or normal saline either at room temperature or at 37 degrees C for 30 minutes and 24 hours, and also at -20 degrees C for six weeks. Samples were then analysed using UPAGE. RESULTS--A maximum decrease in transferrin saturation from (mean (SD)) 93.0 (10.6)% to 54.5 (17.2)% was observed 72.5 (50.0) minutes after deferiprone administration and in most of the patients coincided with peak deferiprone concentration. This was associated with a maximum rise in the percentage of iron free transferrin (apotransferrin) from 2.9 (7.0)% to 27.3 (17.8)%. The total amount of iron estimated to be removed from transferrin constituted 21.3 (20.2)% of the 24 hour urinary iron excretion measured during the study. When deferiprone (150 mumol/l) was incubated in vitro with t0 samples from 10 patients for 30 minutes and 24 hours at room temperature, 37 degrees C, and at -20 degrees C for six weeks, deferiprone was more efficient at removing iron from transferrin at 37 degrees C, with maximum transferrin desaturation accomplished within 30 minutes compared with 24 hours at room temperature. CONCLUSIONS--The results confirm that deferiprone can remove iron from transferrin when administered orally to patients with iron overload and that transferrin bound iron may, therefore, be a significant source of the iron chelated by deferiprone in vivo.

Full text

PDF
110

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agarwal M. B., Gupte S. S., Viswanathan C., Vasandani D., Ramanathan J., Desai N., Puniyani R. R., Chhablani A. T. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol. 1992 Oct;82(2):460–466. doi: 10.1111/j.1365-2141.1992.tb06445.x. [DOI] [PubMed] [Google Scholar]
  2. Evans R. W., Williams J. Studies of the binding of different iron donors to human serum transferrin and isolation of iron-binding fragments from the N- and C-terminal regions of the protein. Biochem J. 1978 Aug 1;173(2):543–552. doi: 10.1042/bj1730543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Flowers C. A., Kuizon M., Beard J. L., Skikne B. S., Covell A. M., Cook J. D. A serum ferritin assay for prevalence studies of iron deficiency. Am J Hematol. 1986 Oct;23(2):141–151. doi: 10.1002/ajh.2830230209. [DOI] [PubMed] [Google Scholar]
  4. Goddard J. G., Kontoghiorghes G. J. Development of an HPLC method for measuring orally administered 1-substituted 2-alkyl-3-hydroxypyrid-4-one iron chelators in biological fluids. Clin Chem. 1990 Jan;36(1):5–8. [PubMed] [Google Scholar]
  5. Kontoghiorghes G. J., Evans R. W. Site specificity of iron removal from transferrin by alpha-ketohydroxypyridine chelators. FEBS Lett. 1985 Sep 9;189(1):141–144. doi: 10.1016/0014-5793(85)80859-0. [DOI] [PubMed] [Google Scholar]
  6. Makey D. G., Seal U. S. The detection of four molecular forms of human transferrin during the iron binding process. Biochim Biophys Acta. 1976 Nov 26;453(1):250–256. doi: 10.1016/0005-2795(76)90270-1. [DOI] [PubMed] [Google Scholar]
  7. Pootrakul P., Josephson B., Huebers H. A., Finch C. A. Quantitation of ferritin iron in plasma, an explanation for non-transferrin iron. Blood. 1988 Apr;71(4):1120–1123. [PubMed] [Google Scholar]
  8. Williams J., Moreton K. The distribution of iron between the metal-binding sites of transferrin human serum. Biochem J. 1980 Feb 1;185(2):483–488. doi: 10.1042/bj1850483. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES